These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32045273)

  • 21. A Case of Ixekizumab-induced Psoriasiform Eruption.
    Oiwa T; Fujita M; Takase S; Nishimura Y; Ota M; Okada K; Tachibana T
    Acta Derm Venereol; 2019 Apr; 99(4):446-447. PubMed ID: 30723870
    [No Abstract]   [Full Text] [Related]  

  • 22. Atezolizumab-induced psoriasiform drug eruption successfully treated with ixekizumab: a case report and literature review.
    Gleason L; Hunter E; Cohen A; Suriano J; Nikbakht N
    Dermatol Online J; 2023 Feb; 29(1):. PubMed ID: 37040912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
    Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
    [No Abstract]   [Full Text] [Related]  

  • 24. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
    Blegvad C; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.
    Azevedo A; Torres T
    Actas Dermosifiliogr; 2017 May; 108(4):305-314. PubMed ID: 27887675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
    Blauvelt A
    Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.
    Hawryluk EB; Linskey KR; Duncan LM; Nazarian RM
    J Cutan Pathol; 2012 May; 39(5):481-92. PubMed ID: 22515220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ixekizumab-treatment-emergent photosensitive cutaneous eruption.
    Anthony E; Rajgopal Bala H; Goh MS; Balta S; Foley P
    Australas J Dermatol; 2018 Nov; 59(4):e284-e286. PubMed ID: 29566260
    [No Abstract]   [Full Text] [Related]  

  • 30. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
    Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
    J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
    Toussirot E
    Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series.
    Napolitano M; Scalvenzi M; Fabbrocini G; Cinelli E; Patruno C
    Dermatol Ther; 2019 Nov; 32(6):e13142. PubMed ID: 31664761
    [No Abstract]   [Full Text] [Related]  

  • 35. IL-17 for therapy.
    Kurschus FC; Moos S
    J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 37. Ixekizumab for treatment of psoriasis.
    Dyring-Andersen B; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2015 Apr; 11(4):435-42. PubMed ID: 25748485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
    Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
    N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.